Rapport Therapeutics (NASDAQ:RAPP) Downgraded to “Sell” Rating by Wall Street Zen

by · The Markets Daily

Wall Street Zen downgraded shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) from a hold rating to a sell rating in a research note released on Saturday.

Other research analysts also recently issued reports about the stock. HC Wainwright lifted their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Citizens Jmp lifted their price objective on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research report on Thursday, January 8th. Finally, BTIG Research reissued a “buy” rating and issued a $47.00 price objective on shares of Rapport Therapeutics in a research note on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.33.

View Our Latest Stock Report on RAPP

Rapport Therapeutics Stock Down 0.2%

RAPP opened at $26.81 on Friday. The firm has a market cap of $1.28 billion, a PE ratio of -9.89 and a beta of 1.63. The business has a fifty day simple moving average of $28.40 and a 200-day simple moving average of $23.26. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. On average, equities research analysts anticipate that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,833 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $29.64, for a total value of $172,890.12. Following the transaction, the chief executive officer directly owned 567,913 shares of the company’s stock, valued at $16,832,941.32. This represents a 1.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Bredt sold 8,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $30.02, for a total value of $255,170.00. Following the sale, the insider directly owned 392,642 shares of the company’s stock, valued at $11,787,112.84. This trade represents a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 56,739 shares of company stock valued at $1,578,630. 13.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RAPP. Capital International Investors raised its position in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after acquiring an additional 800,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Rapport Therapeutics by 46.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,626,538 shares of the company’s stock worth $48,308,000 after purchasing an additional 519,047 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after purchasing an additional 997,000 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Rapport Therapeutics by 4.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock valued at $13,129,000 after purchasing an additional 45,063 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at $28,215,000.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

Featured Stories